{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:28:07Z","timestamp":1789576087771,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T00:00:00Z","timestamp":1619222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T00:00:00Z","timestamp":1619222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s11255-021-02844-4","type":"journal-article","created":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T08:30:51Z","timestamp":1619339451000},"page":"2321-2332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Hyperuricemia and hypertriglyceridemia indicate tubular atrophy\/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy"],"prefix":"10.1007","volume":"53","author":[{"given":"Bingman","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-8492","authenticated-orcid":false,"given":"Xiaoyun","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,24]]},"reference":[{"key":"2844_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2369-15-122","volume":"15","author":"L Li","year":"2014","unstructured":"Li L, Yang C, Zhao Y et al (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122","journal-title":"BMC Nephrol"},{"issue":"6","key":"2844_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1053\/j.jrn.2017.05.002","volume":"27","author":"K Tsuruya","year":"2017","unstructured":"Tsuruya K, Yoshida H, Nagata M et al (2017) Association of hypertriglyceridemia with the incidence and progression of chronic kidney disease and modification of the association by daily alcohol consumption. J Ren Nutr 27(6):381\u2013394","journal-title":"J Ren Nutr"},{"issue":"6","key":"2844_CR3","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1053\/j.ajkd.2015.05.011","volume":"66","author":"K Tsuruya","year":"2015","unstructured":"Tsuruya K, Yoshida H, Nagata M et al (2015) Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of ckd: a longitudinal study in a large Japanese population. Am J Kidney Dis 66(6):972\u2013983","journal-title":"Am J Kidney Dis"},{"key":"2844_CR4","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.12659\/MSM.913506","volume":"25","author":"N Xue","year":"2019","unstructured":"Xue N, Fang Y, Ding X et al (2019) Serum triglycerides are related to chronic kidney disease (CKD) stage 2 in young and middle-aged chinese individuals during routine health examination. Med Sci Monit 25:2445\u20132451","journal-title":"Med Sci Monit"},{"issue":"6","key":"2844_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000502511","volume":"9","author":"PP Toth","year":"2019","unstructured":"Toth PP, Philip S, Hull M et al (2019) Elevated triglycerides (\u2265150 mg\/dL) and high triglycerides (200\u2013499 mg\/dl) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patients. CardioRenal Med 9(6):400\u2013407","journal-title":"CardioRenal Med"},{"issue":"1","key":"2844_CR6","first-page":"e170393","volume":"12","author":"CW Tsai","year":"2017","unstructured":"Tsai CW, Lin SY, Kuo CC et al (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS ONE 12(1):e170393","journal-title":"PLoS ONE"},{"issue":"6","key":"2844_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/nep.12679","volume":"22","author":"YP Hsieh","year":"2017","unstructured":"Hsieh YP, Chang CC, Yang Y et al (2017) The role of uric acid in chronic kidney disease patients. Nephrology 22(6):441\u2013448","journal-title":"Nephrology"},{"issue":"5","key":"2844_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00467-018-3979-2","volume":"34","author":"DJ Weaver","year":"2019","unstructured":"Weaver DJ (2019) Uric acid and progression of chronic kidney disease. Pediatr Nephrol 34(5):801\u2013809","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"2844_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000443415","volume":"41","author":"Y Caliskan","year":"2016","unstructured":"Caliskan Y, Ozluk Y, Celik D et al (2016) The clinical significance of uric acid and complement activation in the progression of IgA nephropathy. Kidney Blood Press Res 41(2):148\u2013157","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"2844_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000489962","volume":"48","author":"B Zhu","year":"2018","unstructured":"Zhu B, Yu DR, Lv JC et al (2018) Uric acid as a predictor of immunoglobulin a nephropathy progression: a cohort study of 1965 cases. Am J Nephrol 48(2):127\u2013136","journal-title":"Am J Nephrol"},{"issue":"1","key":"2844_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ndt\/15.1.34","volume":"15","author":"J Syrjanen","year":"2000","unstructured":"Syrjanen J, Mustonen J, Pasternack A (2000) Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 15(1):34\u201342","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2844_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11255-019-02371-3","volume":"52","author":"J Wang","year":"2020","unstructured":"Wang J, He L, Yan W et al (2020) The role of hypertriglyceridemia and treatment patterns in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis. Int Urol Nephrol 52(2):325\u2013335","journal-title":"Int Urol Nephrol"},{"issue":"8311","key":"2844_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","volume":"2","author":"JF Moorhead","year":"1982","unstructured":"Moorhead JF, Chan MK, El-Nahas M et al (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2(8311):1309\u20131311","journal-title":"Lancet"},{"issue":"3","key":"2844_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.ajkd.2017.08.017","volume":"71","author":"A Srivastava","year":"2018","unstructured":"Srivastava A, Kaze AD, McMullan CJ et al (2018) Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 71(3):362\u2013370","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2844_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","volume":"53","author":"M Madero","year":"2009","unstructured":"Madero M, Sarnak MJ, Wang X et al (2009) Uric acid and long-term outcomes in CKD. Am J Kidney Dis 53(5):796\u2013803","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2844_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/00005344-200109000-00005","volume":"38","author":"WS Waring","year":"2001","unstructured":"Waring WS, Webb DJ, Maxwell SR (2001) Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 38(3):365\u2013371","journal-title":"J Cardiovasc Pharmacol"},{"key":"2844_CR17","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jama.1964.03070220062023","volume":"190","author":"D Berkowitz","year":"1964","unstructured":"Berkowitz D (1964) Blood lipid and uric acid interrelationships. JAMA 190:856\u2013858","journal-title":"JAMA"},{"key":"2844_CR18","first-page":"127596","volume":"2015","author":"TC Peng","year":"2015","unstructured":"Peng TC, Wang CC, Kao TW et al (2015) Relationship between hyperuricemia and lipid profiles in US adults. Biomed Res Int 2015:127596","journal-title":"Biomed Res Int"},{"issue":"5","key":"2844_CR19","first-page":"586","volume":"47","author":"R Zheng","year":"2017","unstructured":"Zheng R, Ren P, Chen Q et al (2017) Serum uric acid levels and risk of incident hypertriglyceridemia: a longitudinal population-based epidemiological study. Ann Clin Lab Sci 47(5):586\u2013591","journal-title":"Ann Clin Lab Sci"},{"key":"2844_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijcard.2018.03.045","volume":"261","author":"M Kuwabara","year":"2018","unstructured":"Kuwabara M, Borghi C, Cicero A et al (2018) Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. Int J Cardiol 261:183\u2013188","journal-title":"Int J Cardiol"},{"issue":"5","key":"2844_CR21","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ki.2009.168","volume":"76","author":"IS Roberts","year":"2009","unstructured":"Roberts IS, Cook HT, Troyanov S et al (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76(5):546\u2013556","journal-title":"Kidney Int"},{"issue":"5","key":"2844_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Cattran DC, Coppo R, Cook HT et al (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76(5):534\u2013545","journal-title":"Kidney Int"},{"issue":"2 Suppl 1","key":"2844_CR23","first-page":"S1","volume":"39","author":"National Kidney Foundation","year":"2002","unstructured":"National Kidney Foundation (2002) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1\u2013S266","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2844_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612","journal-title":"Ann Intern Med"},{"issue":"4","key":"2844_CR25","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1159\/000491809","volume":"43","author":"Y Ruan","year":"2018","unstructured":"Ruan Y, Hong F, Wu J et al (2018) Clinicopathological characteristics, role of immunosuppressive therapy and progression in IgA nephropathy with hyperuricemia. Kidney Blood Press Res 43(4):1131\u20131140","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"2844_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12882-019-1275-4","volume":"20","author":"S Fan","year":"2019","unstructured":"Fan S, Zhang P, Wang AY et al (2019) Hyperuricemia and its related histopathological features on renal biopsy. BMC Nephrol 20(1):95","journal-title":"BMC Nephrol"},{"key":"2844_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2369-15-11","volume":"15","author":"J Zhou","year":"2014","unstructured":"Zhou J, Chen Y, Liu Y et al (2014) Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy. BMC Nephrol 15:11","journal-title":"BMC Nephrol"},{"issue":"1","key":"2844_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/ndt\/gfh584","volume":"20","author":"J Myllymaki","year":"2005","unstructured":"Myllymaki J, Honkanen T, Syrjanen J et al (2005) Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 20(1):89\u201395","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"2844_CR29","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","volume":"78","author":"BN Ames","year":"1981","unstructured":"Ames BN, Cathcart R, Schwiers E et al (1981) Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78(11):6858\u20136862","journal-title":"Proc Natl Acad Sci USA"},{"issue":"32","key":"2844_CR30","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.2174\/138161205774913255","volume":"11","author":"GK Glantzounis","year":"2005","unstructured":"Glantzounis GK, Tsimoyiannis EC, Kappas AM et al (2005) Uric acid and oxidative stress. Curr Pharm Des 11(32):4145\u20134151","journal-title":"Curr Pharm Des"},{"issue":"12","key":"2844_CR31","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3109\/00207454.2015.1134526","volume":"126","author":"D Yang","year":"2016","unstructured":"Yang D, Su Z, Wu S et al (2016) Low antioxidant status of serum bilirubin, uric acid, albumin and creatinine in patients with myasthenia gravis. Int J Neurosci 126(12):1120\u20131126","journal-title":"Int J Neurosci"},{"issue":"4","key":"2844_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s11011-013-9409-z","volume":"28","author":"S Ljubisavljevic","year":"2013","unstructured":"Ljubisavljevic S, Stojanovic I, Vojinovic S et al (2013) Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks. Metab Brain Dis 28(4):629\u2013638","journal-title":"Metab Brain Dis"},{"issue":"6","key":"2844_CR33","doi-asserted-by":"publisher","first-page":"e39738","DOI":"10.1371\/journal.pone.0039738","volume":"7","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, Fang L, Jiang L et al (2012) Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway. PLoS ONE 7(6):e39738","journal-title":"PLoS ONE"},{"issue":"5","key":"2844_CR34","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/ki.2013.251","volume":"84","author":"C Kurts","year":"2013","unstructured":"Kurts C (2013) A crystal-clear mechanism of chronic kidney disease. Kidney Int 84(5):859\u2013861","journal-title":"Kidney Int"},{"issue":"6","key":"2844_CR35","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/HJH.0b013e328337da1d","volume":"28","author":"MA Yu","year":"2010","unstructured":"Yu MA, Sanchez-Lozada LG, Johnson RJ et al (2010) Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 28(6):1234\u20131242","journal-title":"J Hypertens"},{"issue":"2","key":"2844_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/HJH.0b013e3282f240bf","volume":"26","author":"DB Corry","year":"2008","unstructured":"Corry DB, Eslami P, Yamamoto K et al (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26(2):269\u2013275","journal-title":"J Hypertens"},{"issue":"5","key":"2844_CR37","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1681\/ASN.2005090949","volume":"17","author":"C Zoccali","year":"2006","unstructured":"Zoccali C, Maio R, Mallamaci F et al (2006) Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 17(5):1466\u20131471","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2844_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11906-016-0684-z","volume":"18","author":"SG Mallat","year":"2016","unstructured":"Mallat SG, Al KS, Tanios BY et al (2016) Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep 18(10):74","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"2844_CR39","doi-asserted-by":"publisher","first-page":"F471","DOI":"10.1152\/ajprenal.00560.2012","volume":"304","author":"ES Ryu","year":"2013","unstructured":"Ryu ES, Kim MJ, Shin HS et al (2013) Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304(5):F471\u2013F480","journal-title":"Am J Physiol Renal Physiol"},{"key":"2844_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/978-981-13-8871-2_26","volume":"1165","author":"XG Du","year":"2019","unstructured":"Du XG, Ruan XZ (2019) Lipid metabolism disorder and renal fibrosis. Adv Exp Med Biol 1165:525\u2013541","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"2844_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","volume":"67","author":"LG Sanchez-Lozada","year":"2005","unstructured":"Sanchez-Lozada LG, Tapia E, Santamaria J et al (2005) Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67(1):237\u2013247","journal-title":"Kidney Int"},{"issue":"4","key":"2844_CR42","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","volume":"23","author":"LG Sanchez-Lozada","year":"2008","unstructured":"Sanchez-Lozada LG, Tapia E, Soto V et al (2008) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 23(4):1179\u20131185","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2844_CR43","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388\u20131393","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02844-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-021-02844-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02844-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T09:38:44Z","timestamp":1633599524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-021-02844-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,24]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2844"],"URL":"https:\/\/doi.org\/10.1007\/s11255-021-02844-4","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,24]]},"assertion":[{"value":"10 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All of the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is an observational study. The Medical Ethics Committee of the Zhongnan Hospital of Wuhan University has confirmed that no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All of the authors declare their consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}